News

SpeeDx collaborate on test for premature birth risk

Researchers at The University of Western Australia and King Edward Memorial Hospital have teamed up with SpeeDx to commercialise a …

Continue Reading

SpeeDx Raise US $15 million Equity from Northpond Ventures

Up to 15 million equity investment from US-based Northpond Ventures will accelerate commercial expansion in North America and global markets. …

Continue Reading

Health Canada clears ResistancePlus® MG

This is the first commercially available test in Canada combining identification and therapeutic guidance information to support Resistance Guided Therapy …

Continue Reading

SpeeDx sign collaboration agreement with GSK

SpeeDx signed a collaboration agreement with GSK to provide tests and custom test development to support antibiotic clinical trials and …

Continue Reading

FDA Grant Breakthrough Designation for ResistancePlus® GC

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Designation for ResistancePlus® GC – expediting the path towards clearance. …

Continue Reading

PlexPCR® RespiVirus receives TGA clearance for sale in Australia

PlexPCR® RespiVirus received clearance from the Australian Therapeutic Goods Administration (TGA), bringing much needed workflow advantages in time for the …

Continue Reading

Study gauges impact of genotyping on gonorrhea treatment

Dr. Klausner, a clinical professor at UCLA, shares the details of his work with genotypic testing for ciprofloxacin susceptibility in …

Continue Reading

SpeeDx Close Series A Fundraising With Support From U.S. Venture Firm

SpeeDx announced further series A funding received by new investor partners, Northpond Ventures, LP – a U.S.-based, formative stage venture …

Continue Reading

SpeeDx and Cepheid announce test partnership

SpeeDx Pty, Ltd. announced an agreement with Cepheid to manufacture their market-leading ResistancePlus® tests for use on the GeneXpert System. …

Continue Reading

SpeeDx trusted assay partner for Cepheid FleXible for the GeneXpert program

ResistancePlus® MG will be the first test available through Cepheid’s FleXible cartridge program. This partnership will increase access for clinicians …

Continue Reading